Maria Svensson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maria Svensson has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Gisela Dahlquist
Department of Paediatrics, Umeå University Hospital, Umeå, Sweden
3 shared publicationsJan W. Eriksson
Department of Public Health and Clinical Medicine, Medicine, Umeå University, Umeå
3 shared publications- Anna Möllsten
Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden
1 shared publication - Carol Forsblom
Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland
1 shared publication David Sahli
Department of Medicine, Umeå University Hospital, Sweden
1 shared publicationElisabeth Björk
Department of Medicine, Uppsala University Hospital, Uppsala, Sweden
1 shared publication
Latest Publications
- 16 May 2006
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 22 (5) , 401-410
Insulin resistance in diabetic nephropathy — cause or consequence?
Insulin resistance (IR) is associated with multiple risk factors for cardiovascular disease. Many studies have shown that IR is present in chronic renal failure (CRF), and recent evidence suggests that IR can also occur in the early stages of renal disease. Patients with diabetic nephropathy (DN) have an increase in cardiovascular mortality, and since IR may be a contributing factor, this emphasizes the importance of a detailed understanding of the mechanisms linking IR and renal dysfunction at different stages of DN. IR can be detected early on in DN, e.g. at the stage of microalbuminuria (MA) and this could indicate a common genetic trait for IR and DN. As DN progresses further, IR is aggravated and it may, in addition to other factors, possibly accelerate the decline in renal function toward end‐stage renal disease (ESRD). Several potentially modifiable mechanisms including circulating hormones, neuroendocrine pathways and chronic inflammation, are said to contribute to the worsening of IR. In ESRD, uremic toxins are of major importance.In this review article, we address the association between different stages of DN and IR and attempt to summarize major findings on potential mechanisms linking DN and IR. We conclude that IR is a consequence, and potentially also a cause of DN. In addition, there are probably genetic and environmental background factors that predispose to both IR and DN. Copyright © 2006 John Wiley & Sons, Ltd.
- 16 May 2006
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 22 (5) , 401-410
Insulin resistance in diabetic nephropathy — cause or consequence?
Insulin resistance (IR) is associated with multiple risk factors for cardiovascular disease. Many studies have shown that IR is present in chronic renal failure (CRF), and recent evidence suggests that IR can also occur in the early stages of renal disease. Patients with diabetic nephropathy (DN) have an increase in cardiovascular mortality, and since IR may be a contributing factor, this emphasizes the importance of a detailed understanding of the mechanisms linking IR and renal dysfunction at different stages of DN. IR can be detected early on in DN, e.g. at the stage of microalbuminuria (MA) and this could indicate a common genetic trait for IR and DN. As DN progresses further, IR is aggravated and it may, in addition to other factors, possibly accelerate the decline in renal function toward end‐stage renal disease (ESRD). Several potentially modifiable mechanisms including circulating hormones, neuroendocrine pathways and chronic inflammation, are said to contribute to the worsening of IR. In ESRD, uremic toxins are of major importance.In this review article, we address the association between different stages of DN and IR and attempt to summarize major findings on potential mechanisms linking DN and IR. We conclude that IR is a consequence, and potentially also a cause of DN. In addition, there are probably genetic and environmental background factors that predispose to both IR and DN. Copyright © 2006 John Wiley & Sons, Ltd.
- 1 March 2006
- Published by American Diabetes Association in Diabetes Care
- Vol. 29 (3) , 538-542
Age at Onset of Childhood-Onset Type 1 Diabetes and the Development of End-Stage Renal Disease
OBJECTIVE—To analyze the impact of age at onset on the development of end-stage renal disease (ESRD) due to diabetic nephropathy in a nationwide population-based cohort with childhood-onset type 1 diabetes. RESEARCH DESIGN AND METHODS—A record linkage between two nationwide registers, the Swedish Childhood Diabetes Registry, including 12,032 cases with childhood-onset diabetes, and the Swedish Registry for Active Treatment of Uraemia was performed. Log-rank test was used to test differences between cumulative risk curves of developing ESRD due to diabetic nephropathy in three different strata of age at onset (0–4, 5–9, and 10–14 years). RESULTS—At a maximum follow-up of 27 years, 33 patients had developed ESRD due to diabetic nephropathy and all had a diabetes duration >15 years. In total, 4,414 patients had diabetes duration >15 years, and thus the risk in this cohort to develop ESRD was 33 of 4,414 (0.7%). A significant difference in risk of developing ESRD was found between the youngest (0–4 years) and the two older (5–9 and 10–14 years) age-at-onset strata (P = 0.03 and P = 0.001, respectively). A significant difference in the risk of developing ESRD was also found between children with prepubertal (0–4 and 5–9 years, n = 2,424) and pubertal (10–14 years, n = 2000) onset of diabetes (P = 0.002). No patient with onset of diabetes before 5 years of age had developed ESRD. CONCLUSIONS—With a median duration of 21 years in this population-based Swedish cohort with childhood-onset diabetes, <1% of the patients had developed ESRD due to diabetic nephropathy, and a prepubertal onset of diabetes seems to prolong the time to development of ESRD.
- 1 March 2006
- Published by American Diabetes Association in Diabetes Care
- Vol. 29 (3) , 538-542
Age at Onset of Childhood-Onset Type 1 Diabetes and the Development of End-Stage Renal Disease
OBJECTIVE—To analyze the impact of age at onset on the development of end-stage renal disease (ESRD) due to diabetic nephropathy in a nationwide population-based cohort with childhood-onset type 1 diabetes. RESEARCH DESIGN AND METHODS—A record linkage between two nationwide registers, the Swedish Childhood Diabetes Registry, including 12,032 cases with childhood-onset diabetes, and the Swedish Registry for Active Treatment of Uraemia was performed. Log-rank test was used to test differences between cumulative risk curves of developing ESRD due to diabetic nephropathy in three different strata of age at onset (0–4, 5–9, and 10–14 years). RESULTS—At a maximum follow-up of 27 years, 33 patients had developed ESRD due to diabetic nephropathy and all had a diabetes duration >15 years. In total, 4,414 patients had diabetes duration >15 years, and thus the risk in this cohort to develop ESRD was 33 of 4,414 (0.7%). A significant difference in risk of developing ESRD was found between the youngest (0–4 years) and the two older (5–9 and 10–14 years) age-at-onset strata (P = 0.03 and P = 0.001, respectively). A significant difference in the risk of developing ESRD was also found between children with prepubertal (0–4 and 5–9 years, n = 2,424) and pubertal (10–14 years, n = 2000) onset of diabetes (P = 0.002). No patient with onset of diabetes before 5 years of age had developed ESRD. CONCLUSIONS—With a median duration of 21 years in this population-based Swedish cohort with childhood-onset diabetes, <1% of the patients had developed ESRD due to diabetic nephropathy, and a prepubertal onset of diabetes seems to prolong the time to development of ESRD.
- 1 January 2006
- Published by Taylor & Francis in Annals of Medicine
- Vol. 38 (7) , 522-528
Glu298Asp and NOS4ab polymorphisms in diabetic nephropathy
The risk of diabetic nephropathy (DN) increases with increase in intraglomerular pressure, which may partly be regulated by nitric oxide (NO). NO-production can be affected by polymorphisms in the endothelial NO-synthase gene (NOS3), hyperglycaemia and smoking. We therefore studied association between DN and two polymorphisms in NOS3, Glu298Asp and NOS4ab, in Caucasian type 1 diabetes (T1D) patients. A total of 1510 Finnish and Swedish T1D patients were included in a cross-sectional case-control study. Incipient DN was defined as an albumin excretion rate (AER) of 20-200 microg/min (n = 336). Overt DN = AER>200 microg/min or renal replacement therapy (n = 619). All patients with DN were considered as cases. The controls were T1D patients with diabetes duration 20 years, AER<20 microg/min and without antihypertensive treatment (n = 555). The genetic markers studied were a 27 bp repeat (NOS4ab) and Glu298Asp (rs1799983). Age at onset of diabetes, male sex, duration of diabetes, HbA1c, blood pressure and smoking were assessed as possible confounders in the logistic regression analysis, which showed that homozygosity for the Glu-allele of the Glu298Asp-polymorphism was independently associated with increased risk of DN (OR = 1.46; 95% CI = 1.12-1.91). The variables smoking (OR = 2.13; 95% CI = 1.63-2.78), male sex (OR = 1.61; 95% CI = 1.23-2.10), HbA1c (OR per % increase above upper limit of the normal reference range = 1.02; 95% CI = 1.02-1.03), systolic (OR = 1.05; 95% CI = 1.04-1.06) and diastolic blood pressure (OR = 1.04; 95% CI = 1.02-1.05) also significantly and independently increased the risk of DN when taking age at diabetes onset and diabetes duration into account. The NOS4 a-allele was not associated with DN. The Glu/Glu-genotype of the NOS3 Glu298Asp polymorphism may increase the risk of developing DN independently of other known risk factors.
- 1 January 2006
- Published by Taylor & Francis in Annals of Medicine
- Vol. 38 (7) , 522-528
Glu298Asp and NOS4ab polymorphisms in diabetic nephropathy
The risk of diabetic nephropathy (DN) increases with increase in intraglomerular pressure, which may partly be regulated by nitric oxide (NO). NO-production can be affected by polymorphisms in the endothelial NO-synthase gene (NOS3), hyperglycaemia and smoking. We therefore studied association between DN and two polymorphisms in NOS3, Glu298Asp and NOS4ab, in Caucasian type 1 diabetes (T1D) patients. A total of 1510 Finnish and Swedish T1D patients were included in a cross-sectional case-control study. Incipient DN was defined as an albumin excretion rate (AER) of 20-200 microg/min (n = 336). Overt DN = AER>200 microg/min or renal replacement therapy (n = 619). All patients with DN were considered as cases. The controls were T1D patients with diabetes duration 20 years, AER<20 microg/min and without antihypertensive treatment (n = 555). The genetic markers studied were a 27 bp repeat (NOS4ab) and Glu298Asp (rs1799983). Age at onset of diabetes, male sex, duration of diabetes, HbA1c, blood pressure and smoking were assessed as possible confounders in the logistic regression analysis, which showed that homozygosity for the Glu-allele of the Glu298Asp-polymorphism was independently associated with increased risk of DN (OR = 1.46; 95% CI = 1.12-1.91). The variables smoking (OR = 2.13; 95% CI = 1.63-2.78), male sex (OR = 1.61; 95% CI = 1.23-2.10), HbA1c (OR per % increase above upper limit of the normal reference range = 1.02; 95% CI = 1.02-1.03), systolic (OR = 1.05; 95% CI = 1.04-1.06) and diastolic blood pressure (OR = 1.04; 95% CI = 1.02-1.05) also significantly and independently increased the risk of DN when taking age at diabetes onset and diabetes duration into account. The NOS4 a-allele was not associated with DN. The Glu/Glu-genotype of the NOS3 Glu298Asp polymorphism may increase the risk of developing DN independently of other known risk factors.
- 1 May 2005
- Published by Wiley in Clinical Physiology and Functional Imaging
- Vol. 25 (3) , 129-134
Evaluation of simple non-invasive techniques for assessment of lower extremity arterial disease
To evaluate the reproducibility and precision of three, simple, non-invasive methods to measure blood pressure (BP) in the lower extremities by comparing reproducibility and sensitivity in finding abnormally low BP between ankle blood pressure (ABP) and toe blood pressure (TBP), by studying the concordance between TBP in toe 1 and 2 and evaluating the pole-pox method in patients with diabetes and lower extremity arterial disease (LEAD).The BP was measured twice, 1 week apart, in arms and legs in 13 controls and 12 patients with diabetes. ABP was assessed by using a Doppler pen for pulse registration. TBP was obtained by using a small cuff and a pulse oximetry sensor at toe 1 and 2. In eleven patients with diabetes and previously known LEAD ABP was obtained through the pole-pox method.No significant difference in reproducibility between absolute BPs and indices (coefficients of variation <9%) was found. A non-significant improvement with 4-8% in the sensitivity in detecting LEAD was seen when BP indices were used instead of absolute BP. A significant correlation in the variation over time for systemic and TBP (r = 0.34, P = 0.015) and a strong correlation was found between TBP measured at toe 1 and 2, respectively (r = 0.99, P < 0.001) was found. TBP measured with pole-pox method were significantly correlated with measurements made by the ordinary cuff technique (r = 0.75, P < 0.001).The use of TBP and ABP indices instead of absolute BP does not improve the reproducibility but may improve the sensitivity with respect to detection of LEAD, especially in patients with diabetes. The pole-pox method may be used as an alternative screening method in patients with diabetes and LEAD.
- 1 May 2005
- Published by Wiley in Clinical Physiology and Functional Imaging
- Vol. 25 (3) , 129-134
Evaluation of simple non-invasive techniques for assessment of lower extremity arterial disease
To evaluate the reproducibility and precision of three, simple, non-invasive methods to measure blood pressure (BP) in the lower extremities by comparing reproducibility and sensitivity in finding abnormally low BP between ankle blood pressure (ABP) and toe blood pressure (TBP), by studying the concordance between TBP in toe 1 and 2 and evaluating the pole-pox method in patients with diabetes and lower extremity arterial disease (LEAD).The BP was measured twice, 1 week apart, in arms and legs in 13 controls and 12 patients with diabetes. ABP was assessed by using a Doppler pen for pulse registration. TBP was obtained by using a small cuff and a pulse oximetry sensor at toe 1 and 2. In eleven patients with diabetes and previously known LEAD ABP was obtained through the pole-pox method.No significant difference in reproducibility between absolute BPs and indices (coefficients of variation <9%) was found. A non-significant improvement with 4-8% in the sensitivity in detecting LEAD was seen when BP indices were used instead of absolute BP. A significant correlation in the variation over time for systemic and TBP (r = 0.34, P = 0.015) and a strong correlation was found between TBP measured at toe 1 and 2, respectively (r = 0.99, P < 0.001) was found. TBP measured with pole-pox method were significantly correlated with measurements made by the ordinary cuff technique (r = 0.75, P < 0.001).The use of TBP and ABP indices instead of absolute BP does not improve the reproducibility but may improve the sensitivity with respect to detection of LEAD, especially in patients with diabetes. The pole-pox method may be used as an alternative screening method in patients with diabetes and LEAD.
- Open Access
- 1 April 2004
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (4) , 955-962
Early Glycemic Control, Age at Onset, and Development of Microvascular Complications in Childhood-Onset Type 1 Diabetes
OBJECTIVE—The aim of this work was to study the impact of glycemic control (HbA1c) early in disease and age at onset on the occurrence of incipient diabetic nephropathy (MA) and background retinopathy (RP) in childhood-onset type 1 diabetes. RESEARCH DESIGN AND METHODS—All children, diagnosed at 0–14 years in a geographically defined area in northern Sweden between 1981 and 1992, were identified using the Swedish Childhood Diabetes Registry. From 1981, a nationwide childhood diabetes care program was implemented recommending intensified insulin treatment. HbA1c and urinary albumin excretion were analyzed, and fundus photography was performed regularly. Retrospective data on all 94 patients were retrieved from medical records and laboratory reports. RESULTS—During the follow-up period, with a mean duration of 12 ± 4 years (range 5–19), 17 patients (18%) developed MA, 45 patients (48%) developed RP, and 52% had either or both complications. A Cox proportional hazard regression, modeling duration to occurrence of MA or RP, showed that glycemic control (reflected by mean HbA1c) during the follow-up was significantly associated with both MA and RP when adjusted for sex, birth weight, age at onset, and tobacco use as potential confounders. Mean HbA1c during the first 5 years of diabetes was a near-significant determinant for development of MA (hazard ratio 1.41, P = 0.083) and a significant determinant of RP (1.32, P = 0.036). The age at onset of diabetes significantly influenced the risk of developing RP (1.11, P = 0.021). Thus, in a Kaplan-Meier analysis, onset of diabetes before the age of 5 years, compared with the age-groups 5–11 and >11 years, showed a longer time to occurrence of RP (P = 0.015), but no clear tendency was seen for MA, perhaps due to lower statistical power. CONCLUSIONS—Despite modern insulin treatment, >50% of patients with childhood-onset type 1 diabetes developed detectable diabetes complications after ∼12 years of diabetes. Inadequate glycemic control, also during the first 5 years of diabetes, seems to accelerate time to occurrence, whereas a young age at onset of diabetes seems to prolong the time to development of microvascular complications.
- 1 April 2004
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (4) , 955-962
Open AccessEarly Glycemic Control, Age at Onset, and Development of Microvascular Complications in Childhood-Onset Type 1 Diabetes
OBJECTIVE—The aim of this work was to study the impact of glycemic control (HbA1c) early in disease and age at onset on the occurrence of incipient diabetic nephropathy (MA) and background retinopathy (RP) in childhood-onset type 1 diabetes. RESEARCH DESIGN AND METHODS—All children, diagnosed at 0–14 years in a geographically defined area in northern Sweden between 1981 and 1992, were identified using the Swedish Childhood Diabetes Registry. From 1981, a nationwide childhood diabetes care program was implemented recommending intensified insulin treatment. HbA1c and urinary albumin excretion were analyzed, and fundus photography was performed regularly. Retrospective data on all 94 patients were retrieved from medical records and laboratory reports. RESULTS—During the follow-up period, with a mean duration of 12 ± 4 years (range 5–19), 17 patients (18%) developed MA, 45 patients (48%) developed RP, and 52% had either or both complications. A Cox proportional hazard regression, modeling duration to occurrence of MA or RP, showed that glycemic control (reflected by mean HbA1c) during the follow-up was significantly associated with both MA and RP when adjusted for sex, birth weight, age at onset, and tobacco use as potential confounders. Mean HbA1c during the first 5 years of diabetes was a near-significant determinant for development of MA (hazard ratio 1.41, P = 0.083) and a significant determinant of RP (1.32, P = 0.036). The age at onset of diabetes significantly influenced the risk of developing RP (1.11, P = 0.021). Thus, in a Kaplan-Meier analysis, onset of diabetes before the age of 5 years, compared with the age-groups 5–11 and >11 years, showed a longer time to occurrence of RP (P = 0.015), but no clear tendency was seen for MA, perhaps due to lower statistical power. CONCLUSIONS—Despite modern insulin treatment, >50% of patients with childhood-onset type 1 diabetes developed detectable diabetes complications after ∼12 years of diabetes. Inadequate glycemic control, also during the first 5 years of diabetes, seems to accelerate time to occurrence, whereas a young age at onset of diabetes seems to prolong the time to development of microvascular complications.
- 1 October 2003
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (10) , 2903-2909
Signs of Nephropathy May Occur Early in Young Adults With Diabetes Despite Modern Diabetes Management
OBJECTIVE—To estimate the occurrence of early-onset renal involvement in a nationwide population-based cohort of young adults with diabetes in Sweden and relate the findings to glycemic control, type of diabetes, sex, smoking, and blood pressure. RESEARCH DESIGN AND METHODS—The Diabetes Incidence Study in Sweden aims to register all incident cases of diabetes in the age-group 15–34 years. In 1987–1988, 806 patients were reported and invited to participate in a follow-up study focusing on microvascular complications. Of them, 469 subjects participated. The assessment was based on questionnaires (n = 469), blood samples (n = 424), urine samples (n = 251) and, when appropriate, medical records (n = 186). RESULTS—During the follow-up time, median 9 years (range 6–12), 31 of 469 patients (6.6%) with incipient or overt diabetic nephropathy (i.e., micro- or macroalbuminuria) were found, 24 of 426 (5.6%) in type 1 and 7 of 43 (16%) in type 2 diabetic subjects (P = 0.016). Additionally, 24 of 31 patients (77%) had microalbuminuria and 7 (23%) had macroalbuminuria, which mainly occurred in patients with type 2 diabetes. In a Cox regression analysis, high mean HbA1c during the follow-up period and high blood pressure at follow-up increased the risk of developing signs of nephropathy (P = 0.020 and P = 0.003, respectively). Compared with patients with type 1 diabetes, those with type 2 diabetes tended to have an increased risk of renal involvement (P = 0.054) when adjusting for sex, tobacco use, glycemic control, and blood pressure. CONCLUSIONS—Despite modern treatment and self-monitoring of blood glucose, young adult patients with diabetes may still develop renal involvement during the first 10 years of diabetes duration. Inadequate HbA1c, high blood pressure, and type 2 diabetes appear to be risk markers for early occurrence of diabetic nephropathy.
- 1 October 2003
- Published by American Diabetes Association in Diabetes Care
- Vol. 26 (10) , 2903-2909
Signs of Nephropathy May Occur Early in Young Adults With Diabetes Despite Modern Diabetes Management
OBJECTIVE—To estimate the occurrence of early-onset renal involvement in a nationwide population-based cohort of young adults with diabetes in Sweden and relate the findings to glycemic control, type of diabetes, sex, smoking, and blood pressure. RESEARCH DESIGN AND METHODS—The Diabetes Incidence Study in Sweden aims to register all incident cases of diabetes in the age-group 15–34 years. In 1987–1988, 806 patients were reported and invited to participate in a follow-up study focusing on microvascular complications. Of them, 469 subjects participated. The assessment was based on questionnaires (n = 469), blood samples (n = 424), urine samples (n = 251) and, when appropriate, medical records (n = 186). RESULTS—During the follow-up time, median 9 years (range 6–12), 31 of 469 patients (6.6%) with incipient or overt diabetic nephropathy (i.e., micro- or macroalbuminuria) were found, 24 of 426 (5.6%) in type 1 and 7 of 43 (16%) in type 2 diabetic subjects (P = 0.016). Additionally, 24 of 31 patients (77%) had microalbuminuria and 7 (23%) had macroalbuminuria, which mainly occurred in patients with type 2 diabetes. In a Cox regression analysis, high mean HbA1c during the follow-up period and high blood pressure at follow-up increased the risk of developing signs of nephropathy (P = 0.020 and P = 0.003, respectively). Compared with patients with type 1 diabetes, those with type 2 diabetes tended to have an increased risk of renal involvement (P = 0.054) when adjusting for sex, tobacco use, glycemic control, and blood pressure. CONCLUSIONS—Despite modern treatment and self-monitoring of blood glucose, young adult patients with diabetes may still develop renal involvement during the first 10 years of diabetes duration. Inadequate HbA1c, high blood pressure, and type 2 diabetes appear to be risk markers for early occurrence of diabetic nephropathy.
- 1 May 2002
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 34 (5) , 254-259
No Direct Link between Albumin Excretion Rate and Insulin Resistance - A Study in Type 1 Diabetes Patients with Mild Nephropathy
Aims: Albuminuria is thought to be associated with insulin resistance in patients with type 1 and type 2 diabetes as well as in non-diabetic subjects. The aim of this study was to find out about any direct correlation between the albumin excretion rate (AER) and insulin resistance; this was investigated in patients with type 1 diabetes. Methods: Euglycemic hyperinsulinemic clamps were performed in 18 patients with type 1 diabetes and incipient nephropathy - elevated albumin excretion rate (AER > 20 µg/min) but normal glomerular filtration rate (GFR) (81 - 135 ml/min/1.73 m2). Results: AER, determined as mean of two overnight urine collections, was 137 ± 157 (mean ± S.D.) µg/min (range 24 - 447). Insulin sensitivity, expressed as the M-value, was 6.8 ± 2.9 mg/kg/min, insulin sensitivity index (ISI = 100 × M/plasma insulin) 7.9 ± 3.4 and insulin clearance (MCRins) 17.0 ± 4.0 ml/kg/min. Simple regression analyses showed no direct association between AER and M, ISI or MCRins. GFR was not associated with M, ISI or MCRins in this group, either. AER was, however, positively associated with poor glucose control (high HbAlc) and tobacco use. Conclusions: These results suggest that the degree of albuminuria is not directly linked to insulin resistance. This was shown in type 1 diabetics, but could possibly be applicable in other subjects as well.
- 1 May 2002
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 34 (5) , 254-259
No Direct Link between Albumin Excretion Rate and Insulin Resistance - A Study in Type 1 Diabetes Patients with Mild Nephropathy
Aims: Albuminuria is thought to be associated with insulin resistance in patients with type 1 and type 2 diabetes as well as in non-diabetic subjects. The aim of this study was to find out about any direct correlation between the albumin excretion rate (AER) and insulin resistance; this was investigated in patients with type 1 diabetes. Methods: Euglycemic hyperinsulinemic clamps were performed in 18 patients with type 1 diabetes and incipient nephropathy - elevated albumin excretion rate (AER > 20 µg/min) but normal glomerular filtration rate (GFR) (81 - 135 ml/min/1.73 m2). Results: AER, determined as mean of two overnight urine collections, was 137 ± 157 (mean ± S.D.) µg/min (range 24 - 447). Insulin sensitivity, expressed as the M-value, was 6.8 ± 2.9 mg/kg/min, insulin sensitivity index (ISI = 100 × M/plasma insulin) 7.9 ± 3.4 and insulin clearance (MCRins) 17.0 ± 4.0 ml/kg/min. Simple regression analyses showed no direct association between AER and M, ISI or MCRins. GFR was not associated with M, ISI or MCRins in this group, either. AER was, however, positively associated with poor glucose control (high HbAlc) and tobacco use. Conclusions: These results suggest that the degree of albuminuria is not directly linked to insulin resistance. This was shown in type 1 diabetics, but could possibly be applicable in other subjects as well.
- 1 February 2002
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 32 (2) , 100-109
A small reduction in glomerular filtration is accompanied by insulin resistance in type I diabetes patients with diabetic nephrophathy
Background Insulin sensitivity and insulin clearance are compromised in end‐stage renal disease but it has not been fully established whether they are altered in earlier stages of diabetic nephropathy.Design We studied three groups of patients with type 1 diabetes; 10 with no sign of nephropathy, 11 with albuminuria (> 20 µg min−1) but normal glomerular filtration rate (GFR) and eight with a small reduction in GFR, (43–73 mL min−1 1·73 m−2). The groups were matched for age (range 36–61 years), body mass index (BMI), diabetes duration and glycaemic control. The euglycaemic hyperinsulinaemic clamp technique was utilized to study insulin sensitivity (M‐value) and metabolic clearance rate for insulin. Needle biopsies from abdominal subcutaneous fat tissue were obtained to study insulin binding, insulin degradation, insulin‐stimulated glucose uptake and anti‐lipolysis in adipocytes in vitro.Results Patients with reduced GFR were more insulin‐resistant (M‐value 5·7 ± 0·7 mg kg LBM−1 min−1) than those without nephropathy (9·6 ± 0·7, P = 0·001) and those with only albuminuria (8·9 ± 1·2, P = 0·044). In all subjects taken together there was a strong association between insulin sensitivity and GFR (r = 0·46, P = 0·012). Patients with reduced GFR displayed no significant difference in insulin clearance (12·2 ± 1·6 mL kg−1 min−1) compared to controls (13·8 ± 1·3) but a slightly lower insulin clearance than patients with only albuminuria (16·6 ± 1·0, P = 0·027). There were no significant differences between patient groups in the adipocyte studies in vitro, i.e. with respect to insulin binding, insulin degradation and the effects of insulin on glucose uptake and lipolysis. This is compatible with humoral factors causing whole‐body insulin resistance and in the group with reduced GFR, we found that serum parathyroid hormone, interleukin‐6 and tumour necrosis factor‐α levels were elevated whereas the morning cortisol was decreased.Conclusions In type 1 diabetes, the appearance of albuminuria does not seem to alter insulin sensitivity and clearance. A marked insulin resistance but no consistent impairment in insulin clearance seems to accompany progression to a stage with a slight reduction in GFR. These alterations are not accompanied by general defects in insulin target cells. Instead, alterations in the regulation of insulin‐antagonistic hormones and cytokines could potentially contribute to the development of insulin resistance in diabetic nephropathy.
- 1 February 2002
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 32 (2) , 100-109
A small reduction in glomerular filtration is accompanied by insulin resistance in type I diabetes patients with diabetic nephrophathy
Background Insulin sensitivity and insulin clearance are compromised in end‐stage renal disease but it has not been fully established whether they are altered in earlier stages of diabetic nephropathy.Design We studied three groups of patients with type 1 diabetes; 10 with no sign of nephropathy, 11 with albuminuria (> 20 µg min−1) but normal glomerular filtration rate (GFR) and eight with a small reduction in GFR, (43–73 mL min−1 1·73 m−2). The groups were matched for age (range 36–61 years), body mass index (BMI), diabetes duration and glycaemic control. The euglycaemic hyperinsulinaemic clamp technique was utilized to study insulin sensitivity (M‐value) and metabolic clearance rate for insulin. Needle biopsies from abdominal subcutaneous fat tissue were obtained to study insulin binding, insulin degradation, insulin‐stimulated glucose uptake and anti‐lipolysis in adipocytes in vitro.Results Patients with reduced GFR were more insulin‐resistant (M‐value 5·7 ± 0·7 mg kg LBM−1 min−1) than those without nephropathy (9·6 ± 0·7, P = 0·001) and those with only albuminuria (8·9 ± 1·2, P = 0·044). In all subjects taken together there was a strong association between insulin sensitivity and GFR (r = 0·46, P = 0·012). Patients with reduced GFR displayed no significant difference in insulin clearance (12·2 ± 1·6 mL kg−1 min−1) compared to controls (13·8 ± 1·3) but a slightly lower insulin clearance than patients with only albuminuria (16·6 ± 1·0, P = 0·027). There were no significant differences between patient groups in the adipocyte studies in vitro, i.e. with respect to insulin binding, insulin degradation and the effects of insulin on glucose uptake and lipolysis. This is compatible with humoral factors causing whole‐body insulin resistance and in the group with reduced GFR, we found that serum parathyroid hormone, interleukin‐6 and tumour necrosis factor‐α levels were elevated whereas the morning cortisol was decreased.Conclusions In type 1 diabetes, the appearance of albuminuria does not seem to alter insulin sensitivity and clearance. A marked insulin resistance but no consistent impairment in insulin clearance seems to accompany progression to a stage with a slight reduction in GFR. These alterations are not accompanied by general defects in insulin target cells. Instead, alterations in the regulation of insulin‐antagonistic hormones and cytokines could potentially contribute to the development of insulin resistance in diabetic nephropathy.